Xintela receives approval for clinical study with XSTEM® on difficult-to-heal venous leg ulcers
Xintela has today received approval from the Medical Products Agency for a clinical Phase I/IIa study with XSTEM in patients with difficult-to-heal venous leg ulcers. XSTEM consists of integrin α10β1-selected and quality-assured mesenchymal stem cells and is produced in Xintela’s own GMP facility. In the clinical study, which will be carried out in collaboration with […]
Targinta obtains patent grant in Japan
The oncology company Targinta, a wholly owned subsidiary of Xintela AB (publ), announces that the Japanese Patent Office (JPO) has granted a patent covering treatment of tumors of the central nervous system (CNS) using antibodies targeting integrin α10β1. The patent further strengthens Targinta’s intellectual property position and coverage for drug development candidates TARG9 and TARG10. […]
Targinta engages Abzena for the production of TARG9 and TARG10
The oncology company Targinta, a wholly owned subsidiary of Xintela AB (publ), has signed an agreement with Abzena Ltd., the leading global contract development and manufacturing organization (CDMO) providing integrated discovery, development and manufacturing of biologics and antibody-drug conjugates (ADCs), for initial production of the drug candidates TARG9 and TARG10 that are being developed for […]
Xintela AB Interim Report January – March 2022
Summary of the interim reportThe “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480. First quarter 2022» Income amounted to TSEK 0 (0).» Loss before tax totalled TSEK 11,042 (loss: 9,047).» Loss per share* was SEK 0.12 (loss: 0.12).» At March 31, 2022, the equity/assets ratio** was -36 % (16). * Earnings/loss […]
Xintela publishes results showing that XSTEM repairs damaged joint cartilage in preclinical model
Xintela’s results show that its stem cell product XSTEM®, after injection into a joint with damaged cartilage, migrates to the damage and participates in the regeneration of the cartilage tissue. The results have now been published in the scientific journal Stem Cell Research and Therapy. The study is a research collaboration with the University of […]
Notice from annual general meeting in Xintela AB (publ)
Today, Friday 6 May 2022, the annual general meeting in Xintela AB (publ) was held. The following main resolutions were passed. Allocation of results and discharge from liabilityThe meeting resolved, in accordance with the board’s proposal, that no dividend shall be paid for the financial year 2021 and that the company’s result shall be carried […]
Xintela proposes Hans-Joachim Simons as new Board member
Xintela AB (publ) proposes that the company’s shareholders appoint Hans-Joachim Simons as a new member of the Board at the Annual General Meeting on May 6, 2022. Hans-Joachim Simons (born 1962) is the founder and Managing Partner of Bluerock Healthcare Advisors, a dedicated healthcare consultancy firm, and has significant experience in the medtech-, biotech- and […]
Xintela AB’s annual report 2021 published
Xintela AB (publ) has today published its annual report for 2021 on the website www.xintela.se. The annual report is available today in Swedish and an English version will be published shortly. The report is available under financial reports. The financial year refers to the period 1 January – 31 December 2021. The Swedish version of […]
Targinta presents new preclinical data on TARG10 at the AACR Annual Meeting
The oncology company Targinta, a wholly owned subsidiary of Xintela AB (publ), presents new preclinical data on TARG10 at the AACR Annual Meeting (April 8-13) in a poster titled “The integrin α10β1 antibody TARG10 reduces tumor growth and metastasis of triple-negative breast cancer”. Targinta develops first-in-class tumor-targeting antibodies and ADCs against the novel and patent […]
NOTICE OF ANNUAL GENERAL MEETING IN XINTELA AB (PUBL)
The shareholders of Xintela AB (publ) are invited to the annual general meeting on Friday, May 6 2022, at 09.00 CET at Medicon Village, Scheeletorget 1, Building 601 Lund, Sweden. The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail. […]
